The Heal Italia Foundation takes a decisive step toward strengthening its international network, launching the evaluation process for the admission of three new industrial partners of global standing. This strategically significant achievement confirms Heal Italia’s position as a national point of reference and a European hub for innovation in Precision Medicine.
The applications currently under review concern leading players in the international life sciences landscape:
- InnoTech Precision Medicine, based in Boston (USA), within an incubator located near Harvard University. The company specializes in the development of advanced diagnostic platforms for complex diseases and is globally recognized for its ability to translate scientific research into high-impact commercial solutions.
- Sinotide New Drug Discovery Institutes, based in China, an organization dedicated to the development of innovative technologies and therapies with high application potential in the biomedical and pharmaceutical fields, focused on the creation of next-generation therapeutic solutions.
- DCan Biosciences, headquartered in New York (USA), a leading precision medicine company developing next-generation, artificial intelligence–enabled liquid biopsy diagnostics, with a strong track record of collaboration with international industrial partners for clinical and commercial applications.
The opening to these new entities has been made possible by a recent amendment to the Foundation’s bylaws, which expanded membership modalities to allow the admission of international members and industrial partners. This represents a strategic milestone that further strengthens Heal Italia’s global vocation and consolidates its role as a platform connecting research, industry, and investors.
This evolution marks an important step in the Foundation’s development and creates new and tangible opportunities for all members: enhanced access to cutting-edge scientific and technological expertise, expansion of industrial networks, acceleration of technology transfer processes, and entry into new international markets.
With this initiative, Heal Italia increasingly establishes itself as Italy’s Innovation Hub for prevention, diagnostics, and innovative therapies—capable of attracting global excellence and fostering the commercialization of advanced technologies in the biotech and diagnostics sectors. This growth path strengthens the competitiveness of the entire national ecosystem and consolidates Italy’s role within the international life sciences arena.
Companies and organizations interested in joining the Foundation and contributing to the advancement of Precision Medicine may initiate the application process.
For information on membership procedures and requirements, please write to info@healitalia.eu